vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $661.7M, roughly 1.1× SouthState Bank Corp). SouthState Bank Corp runs the higher net margin — 34.1% vs -104.7%, a 138.9% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
QDEL vs SSB — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $661.7M |
| Net Profit | $-733.0M | $225.8M |
| Gross Margin | — | — |
| Operating Margin | -100.7% | 15.1% |
| Net Margin | -104.7% | 34.1% |
| Revenue YoY | -3.7% | — |
| Net Profit YoY | -3583.4% | 153.5% |
| EPS (diluted) | $-10.78 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | — | $581.1M | ||
| Q3 25 | $699.9M | $599.7M | ||
| Q2 25 | $613.9M | $577.9M | ||
| Q1 25 | $692.8M | $544.5M | ||
| Q4 24 | $707.8M | $369.8M | ||
| Q3 24 | $727.1M | $351.5M | ||
| Q2 24 | $637.0M | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | — | $247.7M | ||
| Q3 25 | $-733.0M | $246.6M | ||
| Q2 25 | $-255.4M | $215.2M | ||
| Q1 25 | $-12.7M | $89.1M | ||
| Q4 24 | $-178.4M | $144.2M | ||
| Q3 24 | $-19.9M | $143.2M | ||
| Q2 24 | $-147.7M | $132.4M |
| Q1 26 | — | 15.1% | ||
| Q4 25 | — | 54.3% | ||
| Q3 25 | -100.7% | 53.6% | ||
| Q2 25 | -29.4% | 48.8% | ||
| Q1 25 | 4.7% | 22.3% | ||
| Q4 24 | -14.2% | 50.7% | ||
| Q3 24 | 2.1% | 53.1% | ||
| Q2 24 | -18.4% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | — | 42.6% | ||
| Q3 25 | -104.7% | 41.1% | ||
| Q2 25 | -41.6% | 37.2% | ||
| Q1 25 | -1.8% | 16.4% | ||
| Q4 24 | -25.2% | 39.0% | ||
| Q3 24 | -2.7% | 40.7% | ||
| Q2 24 | -23.2% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | — | $2.47 | ||
| Q3 25 | $-10.78 | $2.42 | ||
| Q2 25 | $-3.77 | $2.11 | ||
| Q1 25 | $-0.19 | $0.87 | ||
| Q4 24 | $-2.54 | $1.88 | ||
| Q3 24 | $-0.30 | $1.86 | ||
| Q2 24 | $-2.20 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $2.9B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | $9.0B |
| Total Assets | $5.7B | $68.0B |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | — | — | ||
| Q3 25 | $98.1M | — | ||
| Q2 25 | $151.7M | — | ||
| Q1 25 | $127.1M | — | ||
| Q4 24 | $98.3M | — | ||
| Q3 24 | $143.7M | — | ||
| Q2 24 | $107.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | — | $9.1B | ||
| Q3 25 | $2.0B | $9.0B | ||
| Q2 25 | $2.8B | $8.8B | ||
| Q1 25 | $3.0B | $8.6B | ||
| Q4 24 | $3.0B | $5.9B | ||
| Q3 24 | $3.2B | $5.9B | ||
| Q2 24 | $3.2B | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | — | $67.2B | ||
| Q3 25 | $5.7B | $66.0B | ||
| Q2 25 | $6.4B | $65.9B | ||
| Q1 25 | $6.5B | $65.1B | ||
| Q4 24 | $6.4B | $46.4B | ||
| Q3 24 | $6.8B | $46.1B | ||
| Q2 24 | $6.7B | $45.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | — |
| Free Cash FlowOCF − Capex | $-94.7M | — |
| FCF MarginFCF / Revenue | -13.5% | — |
| Capex IntensityCapex / Revenue | 7.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $232.1M | ||
| Q3 25 | $-45.5M | $122.4M | ||
| Q2 25 | $-46.8M | $72.6M | ||
| Q1 25 | $65.6M | $-126.3M | ||
| Q4 24 | $63.7M | $354.3M | ||
| Q3 24 | $117.9M | $-246.8M | ||
| Q2 24 | $-97.9M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $215.5M | ||
| Q3 25 | $-94.7M | $101.7M | ||
| Q2 25 | $-84.3M | $52.5M | ||
| Q1 25 | $9.4M | $-139.1M | ||
| Q4 24 | $16.5M | $340.9M | ||
| Q3 24 | $71.4M | $-254.2M | ||
| Q2 24 | $-133.2M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 37.1% | ||
| Q3 25 | -13.5% | 17.0% | ||
| Q2 25 | -13.7% | 9.1% | ||
| Q1 25 | 1.4% | -25.5% | ||
| Q4 24 | 2.3% | 92.2% | ||
| Q3 24 | 9.8% | -72.3% | ||
| Q2 24 | -20.9% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.9% | ||
| Q3 25 | 7.0% | 3.5% | ||
| Q2 25 | 6.1% | 3.5% | ||
| Q1 25 | 8.1% | 2.4% | ||
| Q4 24 | 6.7% | 3.6% | ||
| Q3 24 | 6.4% | 2.1% | ||
| Q2 24 | 5.5% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | -1.42× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -1.72× | ||
| Q2 24 | — | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
